Price movement over the last 24 hours
Alcon AG vs Nerdwallet Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Nerdwallet Inc trades at $9.43 (market cap $625.42M). The key difference: Alcon AG is far larger — about 52.3× Nerdwallet Inc's market cap, and Alcon AG pays a 0.54% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| ALC | NRDS | |
|---|---|---|
Market Cap | $32.69B | $625.42M |
Sector | Health | Financials |
52-Week High | $92.22 | $15.93 |
52-Week Low | $62.02 | $7.58 |
Enterprise Value | $36.28B | $539.72M |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
NRDS trades at $9.50, up 0.32% today, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company shows strong fundamental improvement, with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive to $48.7M. Recent quarters have consistently beaten EPS estimates, and analyst consensus is a Buy with a $12.75 target, implying 34% upside. Positive news highlights the company's pivot to higher-margin transactions and resilience amid search headwinds.
The outlook is positive given strong earnings beats, robust cash flow, and attractive valuation multiples like a P/E of 10.19. Key risks include reliance on search traffic, competitive pressures, and projected negative net cash flow in 2026. Institutional sentiment is bullish, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer finance behavior.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →